N/A N=70 Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
Percutaneous Coronary Intervention · Angiography · Angioplasty
Primary: Time to Achieve Hemostasis — 5.43 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 Capsule Endoscopy in Inflammatory Bowel Disease (IBD) in Children
IBD
Primary: Diagnostic Yield of Magnetic Resonance Enterography (MRE) — 52 % Percentage of Diagnostic yeild
Phase 2 N=23 Olaparib in People With Malignant Mesothelioma
Mesothelioma
Primary: Number of Participants With an Objective Response — 1; 0; 0; 0 Participants
Phase 2 N=38 Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression-free Survival — 424 days
Phase 4 N=50 Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks
Hip Arthroplasty · Hip Pain
Primary: Percent Change From Baseline in Quadriceps Femoris Maximum Voluntary Isometric Contraction (MVIC) — 64.1; 68 percentage change from baseline of MVIC
N/A N=871 Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care
Prevention Harmful Effects
Primary: Time to First Post-visit Drinking Day — 97; 44; 366; 366 days
N/A N=30 Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects
Histological Response of Tissue to Cold
Primary: Biological Tissue Response
Phase 4 N=31 Pain Outcomes Following Intralesional Corticosteroid Injections
Keloid · Alopecia Areata · Acne
Primary: Pain Outcome: Visual Analog Scale — 5.4; 2.7 Score on a scale
Phase 4 N=22 Opioid Free Management After Ureteroscopy
Kidney Stone
Primary: Amount of Pain Medication Used — 7.3; 6.67 tablets
Phase 3 N=120 Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
Human Influenza
Primary: Increase in Geometric Mean Titre Ratio, A/H1N1 Strain — 4.337; 4.702 Ratio of Day 0 and Day 21-28 titres
N/A N=64 RELAX: A Mobile Application Suite Targeting Obesity and Stress
Stress · Weight
Primary: Percentage of Days App Used Over 12 Weeks — 57.5; 53.8 percent of days app used
N/A N=56 AMPLEX Ankle Fusion and Hindfoot
Arthrodesis Surgery Involving the Hindfoot or Ankle
Primary: Proportion of Subjects Who Met All Five Criteria for Subject Performance Composite (SPC) Endpoint — 79.5; 35.3 percentage of subjects
Phase 1 N=40 Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
Migraine
Primary: Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time t (AUC0-t) for Ubrogepant Alone and in Combination With Erenumab — 1841.42; 1959.96…
N/A N=168,477 Consumer Health IT Tools: Impact on Experience, Access, and Outcomes for Patients With Complex Chronic Conditions
Chronic Disease · Patient Outcome Assessment · Electronic Health Records
Primary: Number of Ambulatory Care Sensitive Conditions (ACSC) Hospitalizations. Portal Users vs Those Who Are Not Portal Users — 6.2; 7.0 hospitalizations/1000 participants/month
Phase 3 N=351 A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
Actinic Keratoses
Primary: Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions — 5; 44 percentage of participants — p=<0.0001